A Phase 2 Randomized, Double-blind, Double-dummy Efficacy, Safety And Tolerability Study Of Iv Sulopenem With Switch To Oral Pf-03709270 Compared To Ceftriaxone With Step Down To Amoxicillin/Clavulanate Potassium (Augmentin) In Subjects With Community Acquired Pneumonia (Cap) Requiring Hospitalization

Trial Profile

A Phase 2 Randomized, Double-blind, Double-dummy Efficacy, Safety And Tolerability Study Of Iv Sulopenem With Switch To Oral Pf-03709270 Compared To Ceftriaxone With Step Down To Amoxicillin/Clavulanate Potassium (Augmentin) In Subjects With Community Acquired Pneumonia (Cap) Requiring Hospitalization

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Mar 2016

At a glance

  • Drugs Sulopenem (Primary) ; Sulopenem (Primary) ; Amoxicillin/clavulanic acid; Ceftriaxone
  • Indications Bacterial infections; Community-acquired pneumonia
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 11 Apr 2010 Results presented at the 20th European Congress of Clinical Microbiology and Infectious Diseases.
    • 17 Jul 2009 Actual patient number (35) added as reported by ClinicalTrials.gov.
    • 17 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top